Genmab — Januar 2019
-
Q&A Feb18 - Q: In january you started a “Study to evaluate Subcutaneous Daratumumab in
combination with Standard Multiple Myeloma Treatment Regimens”, which is a Phase
2. You already have the Phase 3 SC vs IV study; could these 2 clinical trials be the
basis for an overall approval of SC in all lines and settings?
Jan : This is a good thought. -
I´ve never understood why split dosing is such a great improvement. You have to take same dosis over 2 days. Same patient must be at the hospital twice as many times and be cleared for treatment. You have to do all the manuel procedures twice against a small time gain ?
-
Mon der er warrants ude? Danske største nettosælger.
-
der vil være en meddelelse fra selskabet aftenen før bølgen af warrants-salg
-
men derfor kan Jan da godt have sluppet en ubehagelig vind over frokostbordet, som får medarbejdere til at sælge ud...
-
Ja...man ved aldrig..!
-
op eller ned?
-
ptjah - det kan vist både blive en dreng og en pige
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind